SAGENT HOLDING CO.

Profile

Company Names

SAGENT HOLDING CO.

Addresses

1901 NORTH ROSELLE ROAD, SUITE 700, SCHAUMBURG, IL 60195

Phone Numbers

847-908-1604

 

Entity Type:

CORPORATION

Industry:

PHARMACEUTICALS

Year Incorporated:

2006

State Incorporated:

CAYMAN ISLANDS

Total Amount Raised:

$45,799,998.00

Number of Funding Rounds:

3
Investment Rounds
Round #
Round Open Date
Amount Raised
Total Round Size
Amount Remaining to be Raised
Securities
3
2010-09-03 
$5,999,998.00 
$5,999,998.00 
$0.00 
Equity 
2
2010-03-24 
$9,800,000.00 
$9,800,000.00 
$0.00 
Equity 
1
2009-05-19 
$30,000,000.00 
$30,000,000.00 
$0.00 
Equity 
People
First Name
Middle Name
Last Name
Titles
Related Companies
ROBERT 
 
FLANAGAN 
DIRECTOR
SAGENT HOLDING CO.   |  SVELTE MEDICAL SYSTEMS INC   |  SNAGFILMS, INC.   |  VASCULAR THERAPIES INC   |  VERAX BIOMEDICAL INC
ANTHONY 
 
KRIZMAN 
DIRECTOR
SAGENT HOLDING CO.
FRANK 
 
KUNG 
DIRECTOR
SAGENT HOLDING CO.   |  REVANCE THERAPEUTICS, INC.   |  NEXTWAVE PHARMACEUTICALS INC   |  VIVO VENTURES VII AFFILIATES FUND, L.P.   |  VIVO CAPITAL FUND VIII, L.P.   |  VIVO CAPITAL SURPLUS FUND VIII, L.P.   |  AMYRIS, INC.   |  VIVO OPPORTUNITY FUND, L.P.   |  VIVO CAPITAL FUND IX, L.P.   |  VIVO OPPORTUNITY CO-INVEST, L.P.   |  VIVO OPPORTUNITY CO-INVEST (W), L.P.   |  VIVO INNOVATION FUND II, L.P.   |  VIVO ASIA OPPORTUNITY FUND, L.P.   |  VIVO OPPORTUNITY CAYMAN FUND, L.P.   |  VIVO CAPITAL FUND X, L.P.
RONALD 
 
PAULI 
EXECUTIVE OFFICER
SAGENT HOLDING CO.   |  HORIZON PHARMA, INC.
RONALD 
E. 
PAULI 
EXECUTIVE OFFICER
SAGENT HOLDING CO.
MARK 
 
QIU 
DIRECTOR
SAGENT HOLDING CO.
JAMES 
 
SPERANS 
DIRECTOR
SAGENT HOLDING CO.   |  MORGAN STANLEY AIP FALCONER GLOBAL EX-U.S. REAL ESTATE 2008 LP   |  MORGAN STANLEY AIP FALCONER GLOBAL REAL ESTATE 2008 LP   |  MORGAN STANLEY GLOBAL SECONDARY OPPORTUNITIES FUND I LP   |  MORGAN STANLEY PRIVATE MARKETS FUND EMPLOYEE INVESTORS V LP   |  MORGAN STANLEY PRIVATE MARKETS FUND V (CAYMAN) L.P.   |  FLINT CAPITAL PARTNERS LP   |  MORGAN STANLEY PRIVATE MARKETS FUND V LP   |  MORGAN STANLEY PREMIUM PARTNERS FUND II L P   |  MORGAN STANLEY PREMIUM PARTNERS FUND II (CAYMAN) L.P.   |  MORGAN STANLEY AIP FALCONER GLOBAL EX-U.S. REAL ESTATE 2010 LP   |  MORGAN STANLEY AIP FALCONER GLOBAL REAL ESTATE 2010 LP   |  MORGAN STANLEY GLOBAL SECONDARY OPPORTUNITIES FUND II LP   |  AIP MPI PARTNERS LP   |  AIP MPI PARTNERS (CAYMAN) L.P.   |  GPF PRIVATE EQUITY FEEDER LP   |  GPF PRIVATE EQUITY LP   |  AIP PRIVATE MARKETS INCOME FUND I LP   |  L CAPITAL PARTNERS LP   |  PRIVATE MARKETS INCOME FUND I LP   |  PMF INTEGRO FUND I LP   |  ASHBRIDGE TRANSFORMATIONAL SECONDARIES FUND I (CAYMAN), LP   |  ASHBRIDGE TRANSFORMATIONAL SECONDARIES FUND I, LP
JEFFREY 
 
YORDON 
EXECUTIVE OFFICER, DIRECTOR
SAGENT HOLDING CO.   |  ATHENEX, INC.   |  AVENACY INC.
CHEN 
 
YU 
DIRECTOR
SAGENT HOLDING CO.   |  NORA THERAPEUTICS, INC.   |  NEXCIDA THERAPEUTICS, INC.   |  OUTPOST MEDICINE, LLC   |  KALA PHARMACEUTICALS, INC.   |  SENTREHEART INC   |  VIVO CAPITAL FUND IX, L.P.   |  TCG CROSSOVER FUND I, L.P.   |  ARBOR BIOTECHNOLOGIES, INC.   |  ADARX PHARMACEUTICALS, INC.   |  LB PHARMACEUTICALS INC
Filings
Filing Date
Filing Type
Source URL
Industry Classifier
Detailed Industry
Revenue Range
Securities
First Sale Date
2010-09-14
D
Link
PHARMACEUTICALS 
 
DECLINE TO DISCLOSE 
Equity 
2010-09-03 
2010-04-05
D
Link
PHARMACEUTICALS 
 
DECLINE TO DISCLOSE 
Equity 
2010-03-24 
2009-06-02
D
Link
PHARMACEUTICALS 
 
DECLINE TO DISCLOSE 
Equity 
2009-05-19 
Brokers
Broker Dealer
Broker CRD#
Recipient Name
Recipient CRD#